• SMV5: Dr. Michael Triplett, CEO of Myonexus Therapeutics on its sale to Sarepta

  • Jun 3 2021
  • Durée: 51 min
  • Podcast

SMV5: Dr. Michael Triplett, CEO of Myonexus Therapeutics on its sale to Sarepta

Écouter gratuitement

Voir les détails du balado

  • Résumé

  • This episode of the SmartMoney Ventures Podcast features Dr. Michael Triplett, CEO of Myonexus Therapeutics who, along with co-founder Dr. Louise Rodino-Klapac, successfully completed a 9 figure exit event before securing Series A financing.

    The story illustrates how successful tech transfer and strategic positioning resulted in the establishment of a new Gene Therapy Center of Excellence creating over 100 new jobs while transforming Muscular Dystrophy patient treatments.

    Prior to co-founding Myonexus, Michael held leadership positions at Proctor & Gamble, Battelle Memorial Institute and Ventaira Pharmaceuticals among others.

    In this episode, you will learn:

    1. How to get a 9 figure exit before your Series A financing
    2. How Technology Transfer is transforming the Heartland Region
    3. Why resilience is a big part of entrepreneurial psychology
    4. Sage advice for technical & scientific founders
    5. How a Gene Therapy Center of Excellence was established in Central Ohio

    Dr. Triplett holds both a bachelor’s degree and a Ph.D. in Chemical Engineering from THE Ohio State University graduating Summa Cum Laude.

    Voir plus Voir moins
Voir plus Voir moins

Ce que les auditeurs disent de SMV5: Dr. Michael Triplett, CEO of Myonexus Therapeutics on its sale to Sarepta

Moyenne des évaluations de clients

Évaluations – Cliquez sur les onglets pour changer la source des évaluations.

Évaluations sur Audible.ca

Évaluations sur Amazon.ca
Il n'y a pas encore de critiques pour ce titre.